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Abstract 
There is an increasing number of applications that have been developed for oligonucleotide-
based biosensing systems in genetics and biomedicine. Oligonucleotide-based biosensors 
are those where the probe to capture the analyte is a strand of DNA, RNA or a synthetic 
analogue to naturally occurring nucleic acids. This chapter will draw light upon various types 
of nucleic acids such as DNA, RNA (particularly microRNAs), their role and their application 
in biosensing. Also, it will cover DNA/RNA aptamers, which can be used as bioreceptors to a 
wide range of targets such as proteins, small molecules, bacteria and even cells. It will also 
highlight how the invention of synthetic oligonucleotides like PNA or LNA has pushed the 
limits of molecular biology and biosensor development to new perspectives. These 
technologies are very promising albeit still in need of development in order to bridge the 
gap between the lab-based status and the reality of biomedical applications. 
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Introduction  
Oligonucleotides are unmodified or chemically modified polymers (DNA or RNA) that are 
relatively small (12-25-mer) introducing an expanded range of applications in molecular 
genetics research and in forensics. The suffix “mer” is often used (derived from the Greek 
for “part”) to denote the length of an oligonucleotide. In the natural world, oligonucleotides 
exist mainly as small noncoding RNAs (e.g. microRNAs). Such oligonucleotides are commonly 
synthesized using solid phase chemistry. Chemical modifications of the sugar-phosphate 
backbone or the bases are often used to increase the stability and half-life of the 
oligonucleotides. In general, oligonucleotides work by hybridizing to their complementary 
sequences. They are used in many different ways including as “primers” in polymerase chain 
reaction (PCR), as “probes” in microarray analysis or in situ hybridisation, and in biosensing 
applications. The explosion of knowledge about gene expression and gene regulation 
mechanisms has led to many new opportunities to develop oligonucleotide-based 
technologies. In order to appreciate these opportunities, this chapter begins with a brief 
overview of the increasing complexity of gene expression. 
 
The complexities of gene expression: a brief summary  
The last decades have witnessed an explosion of knowledge in molecular biology. It is 
increasingly evident that evolution has generated an astonishingly complex set of 
interconnected processes through which gene expression can be regulated. The purpose of 
this section is to provide a general overview of gene expression and to highlight the 
importance of RNA-centred processes in gene regulation.  
In the early days of molecular biology it was thought that transcriptional control was the 
main mechanism through which gene expression is controlled. However, it is abundantly 
clear that epigenetics (including chemical modifications of DNA and of histones, affecting 
how DNA is packaged) and posttranscriptional control (pre-mRNA processing, mRNA 
localisation, translation and stability) are equally important. It is also apparent that all of 
these processes are highly interconnected. What follows is a brief overview of the 
complexities of gene expression. We draw attention particularly to two topics that have 
attracted a lot of interest recently: alternative splicing and noncoding RNAs. 
 
Chromatin, transcription and post-transcriptional regulation 
The regulation of transcription is a fundamental aspect of gene regulation. After all, to be 
expressed, genes need to be transcribed, producing either a messenger RNA (mRNA) or a 
noncoding RNA. Promoters and distal enhancer sequences facilitate the recruitment of RNA 
polymerases and the process of transcription, in which DNA is unwound and one strand 
copied into a complementary RNA transcript, begins at discrete start sites in the genome. In 
vivo DNA does not exist in a ‘naked’ state; instead, it is packaged by proteins into structures 
called nucleosomes by proteins called histones. DNA that is packaged by proteins such as 
histones (or by protamines in sperm cells) is called chromatin. In order for transcription to 
occur, the chromatin structure often needs to be loosened in a process called chromatin 
remodelling. This remodelling occurs following the covalent modification of histones by 
enzymes including histone acetyl transferases, deacetylases, protein kinases and 
methyltransferases. DNA can also be modified directly at CpG positions by methylation of 
cytosine to 5-methylcytosine. Methylated DNA tends to be associated with genes that are 
less transcriptionally active. Chromatin remodelling and DNA modifications, both in 
response to physiological, developmental and environmental cues, do not alter the actual 
base sequence of DNA [1]. However they do alter gene expression in a reversible manner in 
a process called epigenetics (epi is from the Greek for “outside of”).  
The products of transcription, in other words RNA molecules, are called transcripts. In 
general transcripts need to be processed. The precursor of messenger RNA, pre-mRNA, 
needs to be modified at the 5’ end. This consists of a series of covalent modifications to the 
first base (the so-called trimethyl m7G cap). The 5’ cap facilitates nuclear export, mRNA 
translation and mRNA stability. Pre-mRNA is also cleaved at the 3’ end (defining the end of 
the transcript) and polyadenylated. Further complexity arises from the process of pre-mRNA 
splicing, discovered in the late 1970s. In pre-mRNA splicing sequences known as introns are 
precisely removed (spliced) and exons joined together to form the mature mRNA. 
Collectively, capping, splicing, cleavage and polyadenylation are known as pre-mRNA 
processing. They mostly occur co-transcriptionally, i.e. while the RNA polymerase is still 
working its way along the gene. The C-terminus of RNA polymerase II is able to recruit pre-
mRNA processing factors through its heavily phosphorylated C-terminal domain (CTD). The 
process called alternative splicing, in which exons are joined together in different ways, 
results in several transcripts with potentially different coding potential.  
There are several other regulatory processes that occur. RNA editing involves the direct 
chemical modification of RNA bases (e.g. adenine to inosine) potentially altering coding 
potential. mRNA export is a regulated process; incorrectly processed mRNAs are retained in 
the nucleus. In the cytoplasm, mRNA translation, mRNA localization and mRNA stability are 
all highly regulated. Localization allows mRNAs to be delivered to and translated in discrete 
parts of the cytoplasm where the protein is needed such as an axon or lamellipodia. 
Translation consists of three steps, initiation, elongation and termination, each of which is 
highly regulated. The extent to which an mRNA is translated affects how much protein is 
made. Further complexity arises from the presence of occasional alternative translation 
start codons. Messenger RNAs have a half-life; some are more stable than others and an 
mRNA’s half-life has a bearing on how much protein is made. Degradation of mRNA is also 
highly regulated in response to developmental and physiological cues. 
It is quite clear that transcription control is only one of many layers of regulation. Gene 
expression is a highly complex process. Many proteins that are involved in gene regulation 
are multifunctional, facilitating connections between different steps of gene expression. In 
the biosensing field there are opportunities to exploit this complexity. We can illustrate this 
point by turning our attention to two specific examples, alternative splicing and noncoding 
RNAs. 
 
Alternative splicing of pre-mRNA: one gene, multiple transcripts 
When pre-mRNA splicing was first observed in eukaryotic viruses, the discoverers had no 
idea that over 94% of human genes would turn out to be alternatively spliced [3,4]. 
Alternative splicing is the process whereby exons are not always joined together in the same 
way. The main types of alternative splicing are intron retention (sometimes introns are not 
spliced out), cassette exons (exons can be skipped entirely), alternative 5’ and 3’ splice sites 
(in which the boundaries of the exons can change). Through alternative splicing, genes can 
express dozens of splice isoforms. Genes can even produce thousands of transcripts; a 
famous example is the fruit fly Dscam gene [5]. The effect of alternative splicing is to 
augment the size of the proteome very significantly. Splice isoforms often have antagonistic 
functions and their expression is regulated by proteins called splice factors. In the 
biosensing field the existence of multiple, often biologically distinct splice isoforms provides 
the opportunity in the biosensing field to develop ways to detect and measure levels of 
specific splice isoforms.  
The latter point can be illustrated by the example of the HER2 gene. HER2 is a member of 
the human epidermal growth factor receptor family. It is overexpressed in a subset of breast 
cancers and is considered one of the most notable breast cancer biomarkers. HER2 protein 
is targeted by the drug Herceptin, a monoclonal antibody that binds to HER2 and prevents it 
from receiving growth signals. However multiple HER2 splice isoforms have been reported. 
Retention of intron 8 introduces a premature stop codon that results in a truncated 
inhibitory HER2 isoform called herstatin. The isoform HER216 is produced by skipping exon 
16. Exon 16 is 48 bases long and contributes 16 amino-acids in frame to the extracellular 
domain. HER216 forms a constitutively active dimer that is implicated in Herceptin 
resistance [6]. The problem with Herceptin is that it does not discriminate between HER2 
splice isoforms. Thus if a patient’s tumour is already prone to skipping exon 16, resistance to 
Herceptin could arise relatively quickly. Current diagnostic kits in clinical practice only detect 
overall HER2 expression, but they do not measure how it is alternatively spliced. The same 
issue applies to several existing cancer therapies: they do not discriminate splice isoforms. 
There is undoubtedly a need to develop tools that permit the “biosensing” of splice isoforms 
of key biomarkers such as HER2. There are also significant opportunities to use antisense 
oligonucleotides in order to manipulate alternative splicing in vivo. For example splice-
switching oligonucleotides (SSOs) can be designed to block specific 5’ and 3’ splice sites 
facilitating the skipping of disease-associated exons. Antisense oligonucleotides can be used 
to correct splicing defects associated with diseases such as Spinal Muscular Atrophy or 
Duchennes Muscular Dystrophy. The following example illustrates how oligonucleotides can 
be potentially used as anticancer agents. STAT3 is involved in the activation of several 
oncogenic pathways. The splice variant STAT3 arises from an alternative 3’ splice site in 
exon 23; it encodes a truncated pro-apoptotic isoform (in contrast to the oncogenic STAT3 
isoform). A phosphorodiamidate morpholino antisense oligonucleotide was targeted to a 
‘splice enhancer’ sequence that resulted in increased STAT3 expression causing tumour 
regression in a mouse xenograft model [7]. Several hurdles need to be overcome including 
the problems associated with specificity and the need for efficient delivery to target tissues. 
However it is reasonable to predict that in the future antisense oligonucleotides become 
mainstream pharmacological agents. 
 
The increasing importance of noncoding RNAs 
One of the most unexpected recent developments in molecular biology is the finding that 
the genome is rather promiscuous in its transcription, producing a staggering number of 
transcripts that do not encode proteins [8-10]. These are known as noncoding RNAs. 
Noncoding RNAs include ribosomal RNA (rRNA) and transfer RNAs (tRNA) required for 
translation. They also include small noncoding RNAs involved in the processing of other 
RNAs (for example, snRNAs involved in splicing and snoRNAs in pre-rRNA processing). These 
have been known for a long time; however more recently, several other types of noncoding 
RNA have been discovered. They are subdivided into short and long noncoding RNAs. The 
(somewhat arbitrary) definition of a long noncoding RNA is that it is more than 200 
nucleotides in length. 
Long noncoding RNAs (also known as megaRNAs or lncRNAs) are best known for their 
involvement in epigenetic regulation [11]. Long noncoding RNAs are particularly well suited 
to epigenetic regulation because they can bind to complementary target sequences in the 
genome. After binding their genome targets they help recruit proteins that modify 
chromatin. A well-known lncRNA called XIST (X-inactive specific transcript) provides the 
molecular basis of X chromosome inactivation in female mammals [12]. 
Short noncoding RNAs include the microRNAs. MicroRNAs (often abbreviated to miRNA) 
are, when fully processed, quite small (21 nucleotides). They work by binding to target 
mRNAs, generally (but not exclusively) to 3’UTRs (the untranslated sequence that follows 
the stop codon in mRNAs). MicroRNAs are involved in plant and animal physiology and 
development. They work by repressing translation or even causing the targeted degradation 
of mRNAs (Figure 1). The net effect is that microRNAs significantly reduce the amount of 
protein produced by an mRNA; in other words, they repress gene expression post-
transcriptionally. Each miRNA is thought to regulate multiple genes in complex regulatory 
networks. The use of deep sequencing techniques has recently shown that there are even 
more miRNAs in the human genome than originally thought [13]. Aberrant miRNA 
expression is associated with several pathological states. MicroRNAs can be detected in 
blood and urine [14] providing the framework for the development of new biosensing 
technology based on antisense oligonucleotides that are complementary microRNAs 
associated with disease. 
 
Figure 1. Biogenesis and function of microRNAs. MicroRNAs are transcribed by RNA 
polymerase II into primary transcripts called pri-miRNAs which fold into a stemloop 
structure. They are trimmed in the nucleus by a microprocessor complex into pre-mRNAs. 
The latter are then exported with the aid of exportin 5. In the cytoplasm the enzyme Dicer 
further trims the pre-miRNAs into a mature miRNA duplex. The duplex is then complexed by 
Argonaute and other proteins forming mature miRNP complexes (also referred to as miRISC) 
in which only the guide strand of the miRNA is retained. The guide strand is able to bind to 
mRNA targets in the cytoplasm. MiRNAs are also found in P-bodies, cytoplasmic granules 
involved in mRNA turnover. (Reproduced from [2] with permission). 
 
As we have seen in this section, gene expression is an increasingly complex matter. There 
are several opportunities to exploit the advantages of oligonucleotides. They can be used to 
modify and monitor gene expression both in basic research and in gene therapy. 
Oligonucleotides have been used to repress mRNA translation binding mRNAs directly, or to 
block miRNAs, and even to modify pre-mRNA splicing in the nucleus. We now turn our 
attention to DNA aptamers, discussing how they can be modified and used in a variety of 
biosensing applications. 
 
DNA aptamers 
An emerging class of protein binding oligonucleotides are aptamers. These are single 
stranded DNA or RNA sequences that are deliberately designed to bind to a particular 
molecule (including proteins) with high specificity and affinity. They are considered as 
alternatives to antibodies, where they can bind to their targets by undergoing 
conformational changes [15]. An aptamer for a specific target is derived through selective 
rounds of binding followed by amplification in the technique known as SELEX (systematic 
evolution of ligands by exponential enrichment). SELEX has been used to determine which 
DNA or RNA species are bound by proteins of interest. One of the most widely studied DNA 
aptamers was raised against the protein thrombin. On recognising thrombin, it forms a 
signature quadruplex structure by capturing the protein. The thrombin protein is “trapped” 
within the structure and therein it stabilises (figure 2).  
 
Figure 2 - Change in conformation from single stranded DNA aptamer to a quadruplex 
structure upon specific binding with thrombin  
 
Aptamers have many advantages over antibodies making them very important molecular 
tools for both diagnostics and therapeutics. There has been an intense interest in 
understanding the in-depth of ligand-binding and conformational properties. This has led to 
a range of bioassay methods that rely on aptamers as bioreceptors. Aptamers are currently 
widely used in drug delivery application along with a new emerging application as 
bioreceptors in bioassays and in biosensors (termed “aptasensors”). Aptamers can be 
exploited in different methodologies such as electrochemical, optical, mass sensitive, etc 
[16,17]. Although aptamers have many advantages over antibodies, they still face some 
challenges relating to nuclease degradation or reduced binding efficiency because of 
DNA/RNA binding proteins in the blood.  
 
Artificial oligonucleotide analogues 
In recent years, there is hardly a field in biology in which the potential of using synthetic 
oligonucleotides has not been explored. The reason for such a turnover is mainly due to the 
emergence of different molecular cloning techniques along with simultaneous development 
of varied methods for efficient oligonucleotide synthesis. The primary motivations behind 
these developments for the biochemists have been not only the huge biological potential, 
but also immense demand for synthetic oligonucleotides. Synthetic oligonucleotides or 
nucleic acid analogues are compounds which are structurally similar to naturally occurring 
RNA or DNA. Some of the artificial nucleic acids include peptide nucleic acids (PNA), locked 
nucleic acids (LNA), glycol nucleic acids (GNA) and therose nucleic acids (TNA), which differ 
from naturally occurring RNA or DNA in the backbone structure of the molecule. 
Consequently, availability of these synthetic oligonucleotides has led to a revolution in 
solving molecular biology problems along with promising applications in biosensing. This 
section will give an overview on how such synthetic oligonucleotides such as PNA and LNA 
can be transferred from in-solution application to on-surface biosensing applications.  
 
Peptide Nucleic Acids  
Peptide Nucleic Acid (PNA) was first invented by Nielsen et al. in 1991 [18]. PNA is a DNA-
analogue where the sugar phosphate backbone of DNA is replaced by a backbone 
comprising of repeated units of N-(2-aminoethyl) glycine units via amide linkage (Figure 3a). 
Such a modification changes the negative charges of the DNA sugar phosphate backbone to 
a neutral charge of the peptide-like backbone. In a PNA, the four naturally occurring 
nucleobases namely adenine, cytosine, guanine, and thymine are connected to the central 
amine of the peptide backbone via a methylene bridge and a carbonyl group. Therefore, 
PNA sequences are depicted like any peptide with N-terminus at the left end position and C-
terminus on the right end position. 
    
Figure 3. A) Chemical model of a PNA molecule (sequence N-GTA-C) hybridized in 
antiparallel orientation with its complementary DNA (sequence 5′-TAC-3′). The dotted line 
indicates the hydrogen bonding between complementary nucleobases. B) Chemical 
structure of an LNA monomer. (Adapted from [26] with permission from Springer Science 
and Business Media). 
 
Since PNA has a neutral charge and proper interbase spacing, PNA can bind to its 
complementary DNA sequence with higher affinity and specificity following the rules of 
Watson-Crick base-pairing [19]. This is because of reduced electrostatic repulsion between 
PNA/DNA as compared to DNA/DNA. It also results in reduced melting temperatures of the 
PNA/DNA duplex leading to higher thermal stability. Moreover, it has also been 
demonstrated that the stability of a PNA/DNA duplex is essentially independent of the ionic 
strength of the buffer in which hybridisation is performed [20]. 
Because of its unique physicochemical and biochemical properties, PNA as a bioreceptor 
opens up many applications (biological and diagnostic) which would not be achievable with 
naturally occurring oligonucleotides. Many literature reports show how PNA has been 
exploited to detect miRNAs/DNA in biological samples. A range of electrochemical 
techniques have been successfully applied for PNA-based biosensing [21-22]. For example 
Keighley et al. [22] demonstrated how the neutral charge of PNA can be exploited with 
electrochemical impedance spectroscopy: while DNA probes on an electrode offer high 
resistance to negatively charged redox markers in solution [23], neutral PNA probes don’t.; 
upon binding with the complementary strand, a massive increase in resistance was 
observed because of addition of negative charges and increased binding efficiency as 
compared to DNA/DNA. 
 
Locked Nucleic Acids  
Locked nucleic acids (LNA) are another class of synthetic nucleotides which is often referred 
to as inaccessible RNA. LNA was first synthesized by both Imanishi et al. and Wengel et al. in 
1997 [24,25]. It consists of a modified RNA nucleotide, where the ribose moiety is modified 
with an extra bridge that connects the 2’ oxygen and 4’carbon (Figure 3b). Such a linkage via 
a methylene bridge restricts (locks) the ribofuranose into the 3’-endo conformation, which 
is responsible for LNA/DNA or LNA/RNA heteroduplexes [26]. Interestingly, LNA nucleotides 
can be easily mixed with DNA or RNA molecules in the oligonucleotide sequence, which 
greatly improves the thermal stability of LNA/DNA or LNA/miRNA duplexes. LNA, like DNA, 
form specific base pairing with complementary DNA/RNA sequences following Watson-Crick 
rules. By introduction of LNA molecules, the melting temperature can be increased by 2.0 to 
6.0 °C per LNA monomer for LNA/DNA duplex and 3.0–9.6 °C for LNA/RNA duplex [27]. It has 
been reported that LNA forms the strongest duplexes with RNAs which has opened new 
doors for miRNA technology along with DNA detection [28] and biosensors.  
LNA has been used as a probe for microarray technology for detection of multiple miRNAs 
via a novel approach, achieving limits of detection in the attomolar range [29]. Figure 4 
depicts this novel approach where the enzyme reaction is combined with nanoparticle 
amplification using Surface Plasmon Resonance (SPR) as a detection technique. Briefly, a 
poly (A) polymerase was used to extend the miRNAs bound to LNA on the surface with a 
poly (A) tail. Later, gold nanoparticles modified with poly T tails were hybridized with the 
poly (A) tail which could then be detected using SPR.  
 
Figure 4. Schematic showing the detection of microRNAs with nanoparticle amplified SPR 
detection:  (i) specific hybridization of miRNA onto a complementary LNA array; (ii) addition 
of poly(A) tails to the surface-bound miRNAs using poly(A) polymerase enzyme; and (iii) 
hybridization of T30-coated gold nanoparticles (Au NPs) to the poly(A) tails. (Reproduced 
with permission from [29], copyright 2006 American Chemical Society). 
 
Although PNA and LNA have shown to have many advantages over naturally occurring DNA 
or RNA, they still suffer from limitations that include the constraints with length of the 
sequence and composition of bases that can affect the stability of PNA or LNA. This is one of 
the main reasons why PNA or LNA based microarrays are currently not used as high-
throughput biosensors. Nonetheless, biosensors based on artificial analogues are still in 
their early stage of development and exciting new developments are expected as these 
become more mature. 
 
Conclusion 
The use of natural and synthetic nucleotides is still developing and paving the way towards 
advanced biosensor development. It can be seen from literature how researchers from 
different fields are coming together to realise high-throughput oligonucleotide-based 
biosensors for use with complex-matrix samples such as clinical or environmental. The ease 
of manipulation of oligonucleotides, controlled surface chemistry approaches and 
“straightforward” charge distribution, makes them optimal bioreceptors for biosensing 
applications. 
Developments in biochemistry and molecular biology have led to a deeper understanding of 
the role of oligonucleotides and showed that the functions they play are far greater than 
originally expected. This leads to new worlds of biosensing applications, where 
oligonucleotide-based biosensing approaches can have an unparalleled impact in clinical 
diagnosis, prognosis and monitoring, as well as environmental and food control monitoring. 
The increasing demand for enhanced efficiency and to overcome some of the drawbacks of 
using naturally occurring oligonucleotides, has enabled biochemists to come up with 
synthetic analogues such as PNA and LNA, which have further increased the prospects of 
novel biosensing approaches.  
 
Summary 
 DNA-based biosensors can be used for a wide range of applications, from genetic 
identification to pathogen detection and disease diagnosis in biomedical, environmental, 
and forensic applications. 
 The negative charge of DNA or RNA stands makes them ideal biorecognition and/or 
target elements in a range of electrochemical biosensing approaches. 
 MicroRNAs can provide detailed “fingerprints” of diseases and medical conditions. 
 DNA/RNA aptamers are single stranded oligonucleotides that can bind to a range of 
biomolecules with very high affinity through conformational changes. 
 Aptamers can replace antibodies on biosensor development, providing a new way to 
control bioreceptor immobilization, density and orientation onto surfaces, and hence 
the viability of sensitive sensors. 
 Peptide Nucleic Acids and Locked Nucleic Acids are examples of novel synthetic 
DNA/RNA analogues that can provide higher sensitivity and selectivity in biosensors. 
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